Ipsen Publishes its 2018 Registration Document
Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its 2018 Registration Document has been filed with the French “Autorité des Marchés Financiers” (AMF) on 26 March 2019 and registered under the number D.19-0205.
The document is available on the company’s website: www.ipsen.com and on the AMF’s website: www.amf-france.org. Copies are also available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt – France.
The following documents are incorporated into the 2018 Registration Document:
- Annual Financial Report;
- Board of Directors’ Report on corporate governance.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2018 Registration Document available on its website (www.ipsen.com).
Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
Director, Ipsen France Hub, Global Communications
+33 (0) 1 58 33 58 96
Vice President, Investor Relations
+44 (0) 1753 627721
Investor Relations Manager
+33 (0)1 58 33 51 04
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
5G Arrives in Asia as Operators Invest Billions Rolling out Next Generation Networks, Finds New GSMA Study26.6.2019 01:00:00 CEST | Pressemelding
Asia’s mobile operators are set to invest $370 billion building-out new 5G networks between 2018 and 2025, according to the latest Asia Pacific edition of the GSMA’s Mobile Economy series, published at MWC19 Shanghai today. The world’s first nationwide 5G networks went live in South Korea earlier this year, and it is anticipated that 24 Asia Pacific markets will have launched 5G by 2025. It is forecast that 5G will contribute almost $900 billion to the region’s economy over the next 15 years. China is currently testing 5G across all major cities and provinces, including Shanghai, ahead of commercial launches next year. It is forecast that 28 per cent of China’s mobile connections will be running on 5G networks by 2025, accounting for about a third of all 5G connections globally by this point. “Although 4G still has plenty of headroom for growth across Asia, operators in the region are now investing billions in building-out advanced 5G networks that are facilitating an array of new serv
Phunware Offers Phun Utility Token Globally26.6.2019 00:48:00 CEST | Pressemelding
Phunware, Inc. (NASDAQ: PHUN) (the “Company”), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, announced that Phun utility tokens are now available for purchase in international markets. “Phun is a new utility token that enables the international community to participate in our blockchain-enabled data exchange and mobile loyalty ecosystem as we drive towards mainstream global adoption and future exchange listings,” said Randall Crowder, Chief Operating Officer of Phunware. Phunware is an Austin, Texas, headquartered Company with 10 years of success working with the world’s largest organizations. Whether it is enabling immersive gaming and movie experiences for Paramount Pictures International, powering Juniper, Cisco or HP Aruba hardware for app-enabled location services or integrating Electronic Health Records (EHRs) like Epic or Cerner for patient experiences in healthcare, Phunware’s Multiscreen as a
CORRECTING and REPLACING I Squared Capital to Sell Cube Hydro to Ontario Power Generation25.6.2019 23:02:00 CEST | Pressemelding
Sixth paragraph should read: Centerview Partners acted as financial advisor and Sidley Austin LLP, Troutman Sanders LLP, and Davis Polk & Wardwell LLP served as legal counsel to I Squared Capital on this transaction (instead of Centerview Partners acted as financial advisor and Sidley Austin LLP, Troutman Sanders LLP, and David Polk & Wardwell LLP served as legal counsel to I Squared Capital on this transaction). The corrected release reads: I SQUARED CAPITAL TO SELL CUBE HYDRO TO ONTARIO POWER GENERATION I Squared Capital, through its ISQ Global Infrastructure Fund I, announced today that it has reached an agreement to sell its hydropower platform, Cube Hydro Partners and its affiliate, Helix Partners (taken together, Cube Hydro), to Ontario Power Generation (OPG) through its U.S. hydroelectric platform. Cube Hydro owns 385 megawatts of hydro capacity on ten river systems in five states, with 19 small to mid-sized, run-of-the-river and peaking hydro plants. “This is the third portfoli
Results of the MSCI 2019 Market Classification Review25.6.2019 22:15:00 CEST | Pressemelding
MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announces today that it will reclassify the MSCI Kuwait Index to Emerging Markets status, subject to omnibus account structures and same National Investor Number (NIN) cross trades being made available for international institutional investors before the end of November 2019. MSCI will communicate its final decision by December 31, 2019. “Kuwait’s Market Development Project has set the path for the seamless implementation of numerous regulatory and operational enhancements in the Kuwaiti equity market. These enhancements have significantly increased the accessibility level of the Kuwaiti equity market for international institutional investors and resulted in broad positive feedback from these investors on our reclassification proposal,” said Sebastien Lieblich, Global Head of Equity Solutions and Chairman of the MSCI Equity Index Committee. Mr. Lieblich added,
I Squared Capital to Sell Cube Hydro to Ontario Power Generation25.6.2019 19:41:00 CEST | Pressemelding
I Squared Capital, through its ISQ Global Infrastructure Fund I, announced today that it has reached an agreement to sell its hydropower platform, Cube Hydro Partners and its affiliate, Helix Partners (taken together, Cube Hydro), to Ontario Power Generation (OPG) through its U.S. hydroelectric platform. Cube Hydro owns 385 megawatts of hydro capacity on ten river systems in five states, with 19 small to mid-sized, run-of-the-river and peaking hydro plants. “This is the third portfolio company realization in the last twelve months based on the I Squared Capital platform approach, with a total of over $2.8 billion in realized enterprise value,” said Sadek Wahba, Chairman and Managing Partner of I Squared Capital. The other two platforms developed and recently sold by I Squared Capital include Lincoln Clean Energy (a leading onshore wind developer in the U.S. with 800 megawatts) to Ørsted, and Amplus Solar (the preeminent provider of rooftop solar systems for the Indian commercial and in
AerSale Acquires Qwest Air Parts, Inc. to Expand Airframe Parts Sales25.6.2019 19:03:00 CEST | Pressemelding
AerSale ®, a global supplier of aircraft, engines, used serviceable material (USM), and maintenance, repair, and overhaul (MRO) services, announced today it has acquired aircraft parts distributor Qwest Air Parts, Inc. Based in Memphis, Tennessee, Qwest is a recognized leader in aircraft dismantlement and the refurbishment and resale of USM. Qwest has disassembled over 200 aircraft, offers 24/7 AOG service, and operates a teardown facility in Crestview, Florida. Gary Jones, Qwest’s founder, President and CEO, will continue to lead Qwest, which will operate as a stand-alone independent subsidiary of AerSale. The acquisition of Qwest will add scale and reach to AerSale’s already significant airframe USM offerings. Furthermore, Qwest’s recently certified repair station, Q2 Aviation LLC, will supplement AerSale’s growing MRO platform. “As a proven leader in aircraft parts distribution, Qwest is an optimal partner to help further expand our large inventory of high-demand USM, which we cost-